Pfizer Buys Arena For $6.7bn In Bid To Diversify In Inflammation & Immunology
S1P Asset Will Add To JAK-Heavy Pipeline
Executive Summary
The deal is a nod for Arena's turnaround strategy and could be the start of an active deal-making period for Pfizer, flush with cash.
You may also be interested in...
Etrasimod Results Justify Pfizer’s Leap Of Faith In Arena Buyout
Detailed data presented at Digestive Disease Week show competitive efficacy in ulcerative colitis and a potential best-in-class safety profile for the S1P receptor modulator Pfizer acquired earlier this year.
Pfizer To Put Big Marketing Muscle Behind Migraine With Biohaven Purchase
Pfizer’s $11.6bn acquisition of the company brings it full rights to the oral migraine drug Nurtec ODT and nasal spray zevegepant, with aims to build a $6bn migraine franchise.
Pfizer Highlights Next I&I Star As Xeljanz Sales Fall
The company is looking to refuel its immunology & inflammation portfolio as Xeljanz safety takes a toll and the franchise approaches loss of exclusivity.